US FDA acceptance Medicines360's filing for sNDA for Liletta 52 mg
pharmabiz.com | February 24, 2018
Allergan plc, a leading global pharmaceutical company, and Medicines360, a global nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines, announced that the US Food and Drug Administration (FDA) has accepted for filing Medicines360's supplemental New Drug Application (sNDA). The application aims to extend the duration of use for the prevention of pregnancy from up to four years to up to five years for Liletta (levonorgestrel-releasing intrauterine system) 52 mg.